ENDPOINTS NEWS1d
Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions
Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials
The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS ...
ndtvprofit3d
Neuland Labs Share Price Hits Record High As KarXT Gains Focus After AbbVie Drug Setback
Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...
BioSpace4d
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...
Business Insider4d
Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive
or KarXT. This news “may also prove to be a substantial positive” for Neurocrine (NBIX) “if – and it’s admittedly a huge IF – the company can successfully navigate” its own pending Phase 3 program, ...